Jiushi Shenkang Secures Series A Funding Led by Xingze Capital to Advance Neurovascular Interventional Device Pipeline

In June 2020, Beijing NeuroCare Medical Co.,Ltd completed a Series A financing round of nearly RMB 100 million, led by Apricot Capital. The company is primarily engaged in the research and development of neurovascular interventional devices. The funds raised will be used to advance clinical studies of new products in its neurointerventional product pipeline, as well as to support market promotion and industrialization for subsequent product launches.

Beijing NeuroCare Medical Co., Ltd., established in 2016, is an R&D-driven enterprise focused on the research, development, and commercialization of Class III neurointerventional medical devices. Guided by clinical needs, the company has developed a portfolio of therapeutic neurointerventional products covering both ischemic and hemorrhagic stroke. Currently, it offers four major product lines: treatments for intracranial aneurysms, thrombectomy devices for acute ischemic stroke, stroke access systems, and therapies for stenosis. The company’s products under development demonstrate significant market potential and strong competitiveness, with their development stages ranking among the most advanced in China.

Prior to founding Beijing NeuroCare Medical Co., Ltd., its founder, Lü Weiyan, held positions at leading medical device groups, including MicroPort and Lepu Medical. He was responsible for or participated in the R&D and commercialization of more than 20 cardiovascular and cerebrovascular interventional medical devices, successfully bringing several innovative products to market. The company’s core team members hail from multiple leading domestic medical device enterprises, with each member possessing over 10 years of experience in medical device R&D and commercialization.

Apricot Capital, established in 2015, derives its name from the aspiration to leverage capital investment to integrate resources within the broader health industry, thereby promoting sector development and benefiting humanity. The firm currently manages assets exceeding RMB 3 billion. Its investment team comprises more than 20 professionals and advisors with extensive experience in healthcare and medical investments globally, boasting diverse expertise in life sciences, pharmaceuticals, finance, and law.

Since its inception, Apricot Capital has focused on investing in outstanding early-stage and growth-stage enterprises in the healthcare and medical sectors, with a portfolio spanning biopharmaceuticals, medical devices, and related fields. Its portfolio companies include numerous industry leaders such as Junshi Biosciences (01877.HK), Akeso, Inc. (09926.HK), China Antibody (03681.HK), Sinocelltech, MicroPort CardioFlow, Fang En Pharmaceuticals, PharmCube, and Ambrx Biopharma. Committed to fostering innovation and growth among Chinese enterprises and driving industrial progress and social development, Apricot Capital leverages its investment team’s extensive industry experience, global resource network, and esteemed reputation to tirelessly support entrepreneurs in realizing their startup visions.